文献速递肥胖与代谢综合征糖尿病

bimagrumab 慢性抑制肌抑素-激活素通路在健康老年人的心脏安全性

Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

一项随机双盲安慰剂对照研究纳入 68 名 60 至 86 岁健康老年人,评估静脉 bimagrumab 10 mg/kg 治疗 6 个月的心脏安全性。6 个月时左心室质量指数与左室射血分数较安慰剂均无临床相关变化,而全身瘦体重增加 5.5%、脂肪量下降 14%。

要点

  • bimagrumab 治疗 6 个月未引起左心室质量指数或左室射血分数的临床相关变化。
  • bimagrumab 使全身瘦体重增加 5.5%、全身脂肪量下降 14%,两者均 P < .001。
  • 结果支持将 bimagrumab 视为接受 GLP-1 受体激动剂减重者的保肌干预选项。

核心结论

  • 健康老年人接受 bimagrumab 抑制肌抑素-激活素通路 6 个月,与安慰剂相比对心脏结构和功能无影响。
  • 结果支持考虑将 bimagrumab 作为正在使用 GLP-1 受体激动剂减重成人的保骨骼肌干预。

研究设计与样本

  • 随机、双盲、安慰剂对照研究,治疗 6 个月并随访至多 6 个月,单家商业研究站点开展。
  • 共纳入 68 名 60 至 86 岁健康社区居住男女,随机接受静脉 bimagrumab 10 mg/kg 或安慰剂。

主要发现

  • 6 个月时左心室质量指数组间最小二乘均值差 1.6 g/m2(90%CI -0.2 至 3.4),P = .148。
  • 6 个月时左室射血分组间最小二乘均值差 2.0%(90%CI -0.4 至 4.4),P = .176。
  • bimagrumab 组全身瘦体重平均增加 5.5%(标准差 3.6),全身脂肪量平均下降 14%(标准差 8.9),均 P < .001。

关键数值与推荐

  • 左心室质量指数与左室射血分数为主要结局,采用心脏磁共振评估。
  • 瘦体重与脂肪量采用双能 X 线吸收法(DXA)评估。
  • bimagrumab 给药方案为静脉 10 mg/kg。

临床怎么用

  • 对健康老年人短期使用 bimagrumab 未见心脏结构或功能信号,可作为减重期间保肌策略的参考。
  • 心脏安全性数据来自健康老年人 6 个月治疗,尚不能直接外推至肥胖或糖尿病患者的长期使用。

局限性

  • 样本量 68 例、单中心、受试者为 60 至 86 岁健康老年人,随访至多 6 个月。
  • 研究未纳入正在接受 GLP-1 受体激动剂减重的人群,联合用药的心脏安全性未直接验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: GLP-1 receptor agonists have revolutionized the treatment of obesity and type 2 diabetes, but may cause excess muscle loss. Inhibitors of the myostatin-activin pathway can cause fat loss and skeletal muscle gain, but the effect of chronic pathway inhibition on human cardiac muscle is not known. OBJECTIVE: Investigate the effects of extended inhibition of the myostatin-activin pathway on cardiovascular parameters in healthy older adults. DESIGN: Randomized, double-blind, placebo-controlled study with 6 months of treatment and up to 6 months of follow-up. SETTING: Single commercial study site. PARTICIPANTS: 68 healthy community-living men and women aged 60 to 86 years. INTERVENTIONS: Intravenous bimagrumab 10 mg/kg or placebo. MAIN OUTCOME MEASURES: Cardiac magnetic resonance assessment of changes in left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF). Changes in total lean body mass (LBM) and total body fat mass (FM) by dual energy X-ray absorptiometry (DXA). RESULTS: At 6 months, no clinically relevant change was observed in LVMI (least squares mean [90% confidence interval] 1.6 g/m2 [-0.2, 3.4], P = .148) or LVEF (2.0% [-0.4, 4.4], P = .176) between treatments. Total LBM (mean [standard deviation]) increased by 5.5% [3.6], and FM decreased by -14% [8.9] with bimagrumab vs placebo (both P < .001). CONCLUSION: Six months of myostatin-activin pathway inhibition with bimagrumab had no effect on cardiac structure or function in healthy older adults compared to placebo. These results support consideration of bimagrumab as a skeletal muscle-sparing intervention in adults undergoing weight loss with GLP-1 receptor agonists.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rooks D, Yates DP, Neelakantham S, et al. Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults. J Clin Endocrinol Metab. 2026. PMID: 41873146. doi:10.1210/clinem/dgag091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。